|
Market Closed -
Nasdaq
21:00:00 07/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 5.320 USD | -1.12% |
|
-5.51% | -42.92% |
Company Valuation: Aligos Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 505.9 | 40.8 | 49.75 | 147.9 | 57.35 | 33.22 | - | - |
| Change | - | -91.93% | 21.95% | 197.2% | -61.21% | -42.07% | - | - |
| Enterprise Value (EV) 1 | 505.9 | 40.8 | 49.75 | 147.9 | -20.46 | -0.385 | -265 | -163 |
| Change | - | -91.93% | 21.95% | 197.2% | -113.83% | 98.12% | -68,728.75% | 38.5% |
| P/E | -3.69x | -0.42x | -0.49x | -1.9x | -3.8x | -0.82x | -0.99x | -2.04x |
| PBR | 2.74x | - | - | - | 1.72x | 14.6x | 0.61x | 1x |
| PEG | - | 0x | 0x | 0x | 0x | -0x | 0.1x | 0x |
| Capitalization / Revenue | 116x | 2.93x | 5.33x | 37.5x | 26.2x | 0.92x | 7.14x | 0.64x |
| EV / Revenue | 116x | 2.93x | 5.33x | 37.5x | -9.36x | -0.01x | -57x | -3.13x |
| EV / EBITDA | -3.94x | - | - | - | 0.23x | 0x | 2.22x | 1.27x |
| EV / EBIT | -3.94x | -0.42x | -0.56x | -1.66x | 0.23x | 0x | 2.07x | 1.57x |
| EV / FCF | -4.34x | - | - | - | 0.25x | 0x | 2.21x | 1.19x |
| FCF Yield | -23% | - | - | - | 405% | 21,925% | 45.2% | 84.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -80.5 | -56.25 | -34 | -20.94 | -2.45 | -6.478 | -5.374 | -2.614 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4.359 | 13.91 | 9.338 | 3.945 | 2.186 | 35.99 | 4.65 | 52.08 |
| EBITDA 1 | -128.3 | - | - | - | -87.06 | -93.01 | -119.4 | -127.9 |
| EBIT 1 | -128.3 | -97.58 | -88.13 | -89.15 | -87.98 | -84.93 | -127.7 | -103.9 |
| Net income 1 | -128.3 | -96.05 | -87.68 | -131.2 | -24.19 | -79.34 | -124.9 | -101 |
| Net Debt 1 | - | - | - | - | -77.81 | -33.61 | -298.2 | -196.2 |
| Reference price 2 | 296.750 | 23.822 | 16.600 | 39.840 | 9.320 | 5.320 | 5.320 | 5.320 |
| Nbr of stocks (in thousands) | 1,705 | 1,713 | 2,997 | 3,712 | 6,154 | 6,245 | - | - |
| Announcement Date | 10/03/22 | 09/03/23 | 12/03/24 | 10/03/25 | 05/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.83x | -0x | 0x | -.--% | 33.6M | |
| 21.73x | 7.77x | 15.6x | 1.37% | 74.69B | |
| 30.56x | 8.79x | 27.4x | 0.04% | 58.81B | |
| 33.6x | 6.04x | 18.08x | 0.96% | 48.45B | |
| -20.7x | 214.73x | -22.18x | -.--% | 42.84B | |
| 33.49x | 3.25x | 14.04x | -.--% | 42.79B | |
| 48.17x | 5.48x | 30.1x | -.--% | 41.25B | |
| 27.6x | 7.84x | 20.39x | 0.41% | 31.13B | |
| 35.01x | 7.5x | 19.48x | -.--% | 30.28B | |
| -14.91x | 5.52x | -6.94x | -.--% | 24.05B | |
| Average | 19.37x | 26.69x | 11.60x | 0.28% | 39.43B | |
| Weighted average by Cap. | 23.19x | 29.31x | 14.21x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALGS Stock
- Valuation Aligos Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
